<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037981</url>
  </required_header>
  <id_info>
    <org_study_id>vit105</org_study_id>
    <nct_id>NCT05037981</nct_id>
  </id_info>
  <brief_title>Effect of Early Systemic Stabilization Therapy on Recent Onset Vitiligo</brief_title>
  <official_title>Evaluation of Early Systemic Stabilization Therapy on Recent Onset Localized Non-segmental Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitiligo is a distressing disorder of depigmentation. In spite of multiple successful&#xD;
      therapeutic regimens, disease relapse remains a challenge to patients and physicians. Most&#xD;
      guidelines consider systemic treatments only in rapidly progressive disease with wider&#xD;
      surface areas. This delay in halting the immune attack, may give the chance for further&#xD;
      disease progression as well as establishment of resident memory T cell population&#xD;
      predisposing to future disease relapses. The aim of this study was to assess the ability of&#xD;
      early systemic therapy of localized (&lt;2% BSA), recent onset (&lt;6 months) vitiligo to control&#xD;
      disease activity and minimize the possibility of recurrence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2015</start_date>
  <completion_date type="Actual">August 20, 2021</completion_date>
  <primary_completion_date type="Actual">August 10, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Duration needed to arrest of vitiligo activity</measure>
    <time_frame>6 months</time_frame>
    <description>Time needed for vitiligo patients to stop developing new lesions of vitiligo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of maintaining vitiligo stability</measure>
    <time_frame>5 years</time_frame>
    <description>Time before any new vitiligo lesions reappear</description>
  </primary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Vitiligo</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with active localized vitiligo&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 6 years old of both genders&#xD;
&#xD;
          -  Early onset vitiligo (˂6m duration)&#xD;
&#xD;
          -  Body surface area (BSA) affected ≤2%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who received any previous treatment for vitiligo&#xD;
&#xD;
          -  Pregnant and lactating females&#xD;
&#xD;
          -  Patients with other cutaneous or systemic autoimmune diseases&#xD;
&#xD;
          -  Patients with contraindication to systemic corticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samia Esmat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rania Mogawer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dalia Bassiony, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suzan Shalaby, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rehab Hegazy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nanis Ragab, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Ibrahim</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Dina Saadi</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Sharing in published manuscript in a journal</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

